Privacy Policy

 

What This Privacy Policy Covers

This policy covers how Prestium Pharma, Inc. (“we” or “us”) treats personal information that we collect and receive. Personal information is information about you that is personally identifiable like your name, address, email address, or phone number, and that is not otherwise publicly available. This policy does not apply to the practices of companies that we do not own or control, or to people that we do not employ or manage.

Information Collection and Use

We collect personal information about you when you transmit such information to us, and when you visit certain of our pages. We may combine information about you that we have with information we obtain from business partners or other companies. We may use information for the following general purposes: to customize the content you see, fulfill your requests for services, to respond to a job application or inquiry, improve our services, contact you, conduct research, and provide anonymous reporting for internal and external clients. In connection with a job application or inquiry, you may provide us with information about yourself, such as a resume or job application. We may use this information throughout our organization and its related entities for the purpose of employment consideration, and except when you instruct us otherwise, we will keep such information for future consideration. We automatically receive and record information on our server logs from your browser, including your IP Address and the page you request. We do not currently use cookies, but may determine to do so in the future.

Information Sharing and Disclosure

We do not rent, sell, or share personal information about you with other people except to provide services you’ve requested, when we have your permission, or under the following circumstances: we respond to subpoenas, court orders, or legal process, or to establish or exercise our legal rights or defend against legal claims; we believe it is necessary to share information in order to investigate, prevent, or take action regarding illegal activities; violations of our Terms and Conditions, or as otherwise required by law; and we transfer information about you if we are acquired by or merged with another company.

Confidentiality and Security

We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions. We are committed to protecting personal information from loss, misuse, disclosure, alteration, unauthorized access and destruction. We take all reasonable precautions to safeguard the confidentiality of personally identifiable information. We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions.

Changes to this Privacy Policy

We may modify this policy at our sole discretion at any time. We will notify you about significant changes in the way we treat personal information by placing a prominent notice on our site.

 Effective Date: 8.10.2012

 

 

 

 


IMPORTANT SAFETY INFORMATION


Full Prescribing Information


  • LUXIQ® (betamethasone valerate) Foam, 0.12% is for topical use only.

  • Systemic absorption of topical corticosteroids has caused reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of the topical corticosteroid.

  • Manifestations of Cushing’s Syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids.

  • Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Evaluate patients periodically for evidence of HPA axis suppression.

  • If irritation develops, LUXIQ Foam should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids.

  • Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection persists, LUXIQ Foam should be discontinued until the infection has been adequately treated.

  • LUXIQ Foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

  • Caution should be exercised when LUXIQ Foam is administered to a nursing woman.

  • Safety and efficacy in pediatric patients have not been established. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin to surface body mass ratios. Chronic corticosteroid therapy may interfere with the growth and development of children.

  • In clinical studies, the most common adverse events associated with the use of LUXIQ Foam were burning, stinging, or itching at the application site.

  • Local adverse reactions that have been reported with topical steroids include: irritation; dryness; folliculitis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; secondary infection; skin atrophy; striae; and malaria.

  • Because LUXIQ Foam is flammable, you should counsel patients to avoid fire, flame, or smoking during and immediately following application.








LUXIQ is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.